Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice

Jean‐Philippe Pradere, Johannes Kluwe, Samuele Minicis, Jing‐Jing Jiao, Geum‐Youn Gwak, Dianne H. Dapito, Myoung‐Kuk Jang, Nina D. Guenther, Ingmar Mederacke, Richard Friedman, Ana‐Cristina Dragomir, Costica Aloman, Robert F. Schwabe – 28 March 2013 – Although it is well established that hepatic macrophages play a crucial role in the development of liver fibrosis, the underlying mechanisms remain largely elusive. Moreover, it is not known whether other mononuclear phagocytes such as dendritic cells (DCs) contribute to hepatic stellate cell (HSC) activation and liver fibrosis.

Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale‐up in the age of direct‐acting antivirals

Natasha K. Martin, Peter Vickerman, Jason Grebely, Margaret Hellard, Sharon J. Hutchinson, Viviane D. Lima, Graham R. Foster, John F. Dillon, David J. Goldberg, Gregory J. Dore, Matthew Hickman – 28 March 2013 – Substantial reductions in hepatitis C virus (HCV) prevalence among people who inject drugs (PWID) cannot be achieved by harm reduction interventions such as needle exchange and opiate substitution therapy (OST) alone.

An alpaca nanobody inhibits hepatitis C virus entry and cell‐to‐cell transmission

Alexander W. Tarr, Pierre Lafaye, Luke Meredith, Laurence Damier‐Piolle, Richard A. Urbanowicz, Annalisa Meola, Jean‐Luc Jestin, Richard J. P. Brown, Jane A. McKeating, Felix A. Rey, Jonathan K. Ball, Thomas Krey – 28 March 2013 – Severe liver disease caused by chronic hepatitis C virus is the major indication for liver transplantation. Despite recent advances in antiviral therapy, drug toxicity and unwanted side effects render effective treatment in liver‐transplanted patients a challenging task.

Subscribe to